Legend Biotech Reports First Quarter 2025 Results and Recent Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/26/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Fox Factory sells Marucci Sports for $225M, cuts debt
TD Cowen Reiterates Buy Rating on Legend Biotech Corp. (LEGN), PT $62, 'We Like The Profile At These Levels'
May 13, 2025 4:38 PM EDTTD Cowen analyst Yaron Werber reiterated a Buy rating and $62.00 price target on Legend Biotech Corp. (NASDAQ: LEGN).
The analyst comments "Our Take: Carvykti Continues Solid Ramp, With Growth Likely Weighted Towards H2:25 We Like The Profile At These Levels We like the risk/reward of the stock at these levels given a solid sales ramp for Carvykti on the heels of strong demand, especially in... More
